Could an immune drug slow down multiple myeloma before it starts?

NCT ID NCT05014646

First seen Mar 15, 2026 · Last updated May 16, 2026 · Updated 10 times

Summary

This phase 2 trial tests whether leflunomide, a drug that calms the immune system, can delay the start of multiple myeloma in people with high-risk smoldering multiple myeloma. The study includes 27 African-American and European-American participants. Researchers are tracking how many patients progress to active myeloma and any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Atrium Health University City/LCI-University

    Charlotte, North Carolina, 28204, United States

  • City of Hope Medical Center

    Duarte, California, 91010, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Wayne State University/Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

Conditions

Explore the condition pages connected to this study.